Immunity Pharma (IPL) develops therapies for neurodegenerative diseases with an initial focus on amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

miCure Therapeutics is a biotechnology company leveraging microRNA-based therapeutics and diagnostics for neurodegenerative and psychiatric disorders.

Neurogenic is a clinical-stage diagnostics company advancing the development of a novel ELISA-based immunoassay to detect pathological Platelet-Associated Antibodies (PAA) in the sera of adolescent and pediatric patients to facilitate the diagnosis of early-onset schizophrenia.

SynVaccine has developed a CAD/CAM platform for designing and fabricating designer viruses for biotechnology.

NanoCell Ltd. is dedicated to advancing women’s reproductive health through biopharmaceutical technologies that significantly improve embryo implantation, consequently increasing the chances of conceiving.

ImmunoBrain Checkpoint (IBC) is a biopharmaceutical company focused on developing a pipeline of disease-modifying immunotherapies for neurological disorders by targeting immune checkpoint pathways.

FreezeM offers a technology designed to improve the use of insects as a protein source for animal feed. Its products are designed to overcome a number of the limitations of using insects as a protein source, including cost, availability, and regulatory concerns.

The first innovative drug to be developed in Israel and to receive FDA approval, Copaxone® is a unique multiple sclerosis immunomodulator: the first and only non-interferon agent for the treatment of relapsing-remitting multiple sclerosis.  Copaxone® is licensed to Teva Pharmaceuticals Ltd.

An antibody based therapy presenting synergism with conventional chemotherapy. The synergistic effect was invented at the Weizmann Institute. Erbitux was developed by ImClone Systems and approved by the FDA in 2001.